- Home
- QS vs MDGL Comparison
QS vs MDGL Comparison
Compare QS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- MDGL
- Stock Information
- Founded
- QS 2010
- MDGL 2011
- Country
- QS United States
- MDGL United States
- Employees
- QS N/A
- MDGL N/A
- Industry
- QS Auto Parts:O.E.M.
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- MDGL Health Care
- Exchange
- QS Nasdaq
- MDGL Nasdaq
- Market Cap
- QS 8.8B
- MDGL 9.6B
- IPO Year
- QS N/A
- MDGL N/A
- Fundamental
- Price
- QS $11.80
- MDGL $549.26
- Analyst Decision
- QS Sell
- MDGL Strong Buy
- Analyst Count
- QS 7
- MDGL 13
- Target Price
- QS $8.07
- MDGL $539.00
- AVG Volume (30 Days)
- QS 38.2M
- MDGL 428.3K
- Earning Date
- QS 10-22-2025
- MDGL 11-04-2025
- Dividend Yield
- QS N/A
- MDGL N/A
- EPS Growth
- QS N/A
- MDGL N/A
- EPS
- QS N/A
- MDGL N/A
- Revenue
- QS N/A
- MDGL $740,640,000.00
- Revenue This Year
- QS N/A
- MDGL $395.75
- Revenue Next Year
- QS N/A
- MDGL $65.73
- P/E Ratio
- QS N/A
- MDGL N/A
- Revenue Growth
- QS N/A
- MDGL 864.21
- 52 Week Low
- QS $3.40
- MDGL $265.00
- 52 Week High
- QS $19.07
- MDGL $577.90
- Technical
- Relative Strength Index (RSI)
- QS 36.79
- MDGL 68.83
- Support Level
- QS $14.84
- MDGL $505.00
- Resistance Level
- QS $16.22
- MDGL $577.90
- Average True Range (ATR)
- QS 1.44
- MDGL 30.54
- MACD
- QS -0.57
- MDGL 7.06
- Stochastic Oscillator
- QS 0.16
- MDGL 82.13
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.